[literature] The glucagon arm is the differentiator behind retatrutide’s class-leading Phase 3 weight loss (up to 28.3%, TRIUMPH-1 2026) vs GLP-1/GIP-only agents — adding energy expenditure/hepatic-fat effects atop appetite suppression. — SOURCE-retatrutide-triumph1-phase3
[literature] The glucagon-arm’s hepatic/visceral-fat signature shows clearly in the glucagon/GLP-1 dual agonist survodutide (SYNCHRONIZE-1, ADA 2026): 16.6% weight loss but visceral fat ↓34% and liver fat ↓63% — glucagon receptor activation targeting the liver, not just appetite. — SOURCE-survodutide-synchronize1-phase3-2026